These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 28341110)
1. Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs. Matsuoka H; Kaneda H; Sakai K; Koyama A; Nishio K; Nakagawa K Clin Lung Cancer; 2017 Jan; 18(1):e85-e87. PubMed ID: 28341110 [No Abstract] [Full Text] [Related]
2. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer. Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure. Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140 [TBL] [Abstract][Full Text] [Related]
4. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
5. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Takeda M; Okamoto I; Nakagawa K Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957 [TBL] [Abstract][Full Text] [Related]
6. Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question. Giuliani J; Martelli S; Remo A; Bonetti A Tumori; 2015 Jul; 101(4):e115-7. PubMed ID: 25953440 [TBL] [Abstract][Full Text] [Related]
8. Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. Jakubowski CD; Plodkowski AJ; Chang JC; Rekhtman N; Iqbal A; Paik PK; Yu HA Clin Lung Cancer; 2017 Jan; 18(1):e81-e83. PubMed ID: 27863924 [No Abstract] [Full Text] [Related]
9. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer. Lin YT; Liu YN; Wu SG; Yang JC; Shih JY Clin Lung Cancer; 2017 May; 18(3):324-332.e1. PubMed ID: 28089594 [TBL] [Abstract][Full Text] [Related]
10. Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study. Matam K; Goud I; Lakshmi M AM; Ravi V; Sridhar K; Vijayanand PR; Chakravarthy S; Prasad SV; Tabassum SN; Shaik NA; Syed R; Alharbi KK; Khan IA Asian Pac J Cancer Prev; 2015; 16(16):7071-6. PubMed ID: 26514492 [TBL] [Abstract][Full Text] [Related]
11. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation. Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841 [TBL] [Abstract][Full Text] [Related]
12. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors. Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562 [TBL] [Abstract][Full Text] [Related]
13. Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations. Nishinarita N; Igawa S; Kasajima M; Kusuhara S; Harada S; Okuma Y; Sugita K; Ozawa T; Fukui T; Mitsufuji H; Yokoba M; Katagiri M; Kubota M; Sasaki J; Naoki K Oncology; 2018; 95(2):109-115. PubMed ID: 29698957 [TBL] [Abstract][Full Text] [Related]
14. De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. Takeda M; Okamoto I; Fujita Y; Arao T; Ito H; Fukuoka M; Nishio K; Nakagawa K J Thorac Oncol; 2010 Mar; 5(3):399-400. PubMed ID: 20186026 [TBL] [Abstract][Full Text] [Related]
15. Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer. Lopes GL; Vattimo EF; Castro Junior Gd J Bras Pneumol; 2015; 41(4):365-75. PubMed ID: 26398757 [TBL] [Abstract][Full Text] [Related]
16. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis. Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835 [TBL] [Abstract][Full Text] [Related]
17. Antitumoral activity of tyrosine kinase inhibitors in patients with non-small cell lung cancer harbouring rare epidermal growth factor receptor mutations. Oyaert M; Demedts I; Boone E; Dedeurwaerdere F; Vandorpe J; De Laere E; Breyne J Mol Diagn Ther; 2015 Oct; 19(5):267-72. PubMed ID: 26266520 [TBL] [Abstract][Full Text] [Related]
18. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments. Wang DD; Ma L; Wong MP; Lee VH; Yan H PLoS One; 2015; 10(5):e0128360. PubMed ID: 25993617 [TBL] [Abstract][Full Text] [Related]
19. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Becker A; Crombag L; Heideman DA; Thunnissen FB; van Wijk AW; Postmus PE; Smit EF Eur J Cancer; 2011 Nov; 47(17):2603-6. PubMed ID: 21784628 [TBL] [Abstract][Full Text] [Related]
20. EGFR mutations in lung cancer: from tissue testing to liquid biopsy. Fenizia F; De Luca A; Pasquale R; Sacco A; Forgione L; Lambiase M; Iannaccone A; Chicchinelli N; Franco R; Rossi A; Morabito A; Rocco G; Piccirillo MC; Normanno N Future Oncol; 2015; 11(11):1611-23. PubMed ID: 26043215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]